IgG vs Fab neutralization

In Simonich et al (2025), we explain why mutations to RSV F can have different impacts on IgG versus Fab neutralization depending on the affinity of the Fab for the F variant (these affinities differ for nirsevimab between subtype A and B RSV).

A quantitative biophysical model that explains these differences is available here, and below is an interactive plot that allows you to explore these effects interactively: